Auxilium Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Auxilium Pharmaceuticals's estimated annual revenue is currently $32.4M per year.
- Auxilium Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Auxilium Pharmaceuticals has 161 Employees.
- Auxilium Pharmaceuticals grew their employee count by -1% last year.
Auxilium Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Biometrics | Reveal Email/Phone |
2 | Area director, medical affairs | Reveal Email/Phone |
3 | Global Safety Surveillance Manager | Reveal Email/Phone |
4 | Sr. QA Manager | Reveal Email/Phone |
5 | Maintenance Manager | Reveal Email/Phone |
6 | Associate Manager, Manufacturing, Packaging and Inventory | Reveal Email/Phone |
7 | Reimbursement Account Manager | Reveal Email/Phone |
8 | Sales | Reveal Email/Phone |
9 | Specialty Account Manager | Reveal Email/Phone |
10 | Qc Chemist | Reveal Email/Phone |
Auxilium Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Auxilium Pharmaceuticals?
Auxilium Pharmaceuticals, Inc. was acquired by Endo in January 2015. Auxilium Pharmaceuticals, Inc. is a fully integrated specialty biopharmaceutical company with a focus on developing and commercializing innovative products for specialist audiences. At Auxilium, everything we do is inspired by a commitment to our mission, vision and values. Our mission is to improve the lives of patients throughout the world by successfully identifying, developing and commercializing innovative specialty biopharmaceutical products. We are committed to the long-term success of our employees and shareholders, providing new treatment options to healthcare professionals and the welfare of patients. Our vision is to become one of the most successful and admired companies within the specialty pharmaceutical industry. We are guided by the principle that both “what†we do and “how†we do it serve as the roadmap for achieving our goals and are driven by our fundamental core values: Spirit of Innovation, Personal Leadership, Performance Driven, Focus on People, Integrity and Compliance, and Customer Commitment. We believe that what makes a company great is truly the quality and job satisfaction of its people. At Auxilium, our people are bound by a common vision, core set of values and a commitment to making a difference in the lives of patients. We strive to cultivate a team-oriented culture where employees feel appreciated, have the opportunity to grow professionally and add value. We offer an exciting work environment and are located outside of Philadelphia, Pennsylvania, one of the nation's largest biotechnology regions. If you would like to join our team, we invite you to review our open positions and apply at http://auxilium.com/careers/.
keywords:N/AN/A
Total Funding
161
Number of Employees
$32.4M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Auxilium Pharmaceuticals News
STENDRA® (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals,...
Menarini Group; Auxilium Pharmaceuticals; Endo International; JW Pharmaceutical. This record is divided into numerous distinct regions, one of...
Before Adapt Pharmaceutical, Mr. Karas was credited with being at the forefront of Auxilium Pharmaceuticals' growth during his eight-year...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $47.8M | 161 | 7% | N/A |
#2 | $18.1M | 161 | 14% | N/A |
#3 | $25.7M | 161 | 22% | N/A |
#4 | $45M | 161 | -22% | N/A |
#5 | $17.7M | 161 | 5% | N/A |